Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
1. Akero's EFX shows 39% cirrhosis reversal in treated patients. 2. Effect size of 24% over placebo indicates significant efficacy. 3. Longer treatment led to doubled effect size from weeks 36 to 96. 4. EFX is generally well-tolerated with few adverse events reported. 5. AKRO stock surged 112.5% to $55.60 in premarket trading.